bioweapon news from Shanghai and Germany

With genetically modified snake venom, parasites, graphene nanoparticles and lipid nanoparticles, both crossing blood-brain barrier, the world’s leading manufacturer of bioweapons/genetic-modifier of DNA in world’s individuals taking these “safe” drugs, with big big backing deals— Fosun has operations in New Jersey and rapidly is striving to be world leader if it is not already so. The Opium War/covert manipulations of 19th century are being surpassed. And then there's AIDS stuff, cancer stuff and ADE stuff as well in these "medicines" to reduce world's population. -r., 12-2-2022 ………….. May 10, 2021 A Shanghai-based pharmaceutical company is planning to produce a COVID-19 vaccine with one of the highest known efficacy rates after sealing a deal with its foreign counterpart. The deal between Shanghai Fosun Pharmaceutical Group and its German partner BioNTech will allow for the domestic production of 1 billion doses of the messenger RNA (mRNA) COVID-19 vaccines annually, the Chinese company said Sunday in a stock filing to the Shanghai Stock Exchange. The mRNA vaccine was co-developed by BioNTech and U.S. pharmaceutical company Pfizer, and is 95% effective in preventing COVID-19. https://www.sixthtone.com/news/1007409/chinese-firm-signs-deal-to-produce-pfizer-biontech-vaccine ……… By Su Yung-yao and Kayleigh Madjar / Staff reporter Beijing has been encouraging Taiwanese organizations to purchase Pfizer-BioNTech COVID-19 vaccines through Shanghai Fosun Pharmaceutical Group to give the impression that all vaccines received by Taiwanese after this summer came from China, industry sources said yesterday. Chinese officials are urging groups to follow the example of Taiwan Semiconductor Manufacturing Co and Hon Hai Precision Industry Co, which are looking to purchase millions of doses through a subsidiary of the Chinese company, they said. Shanghai Fosun has a contract with Germany’s BioNTech to sell the vaccine in Taiwan, China, Hong Kong and Macau https://www.taipeitimes.com/News/taiwan/archives/2021/07/06/2003760380 …….. Fosun Pharma will inject a maximum of $100 million into its joint venture with BioNTech to build factories and facilities, while the German company will provide the patent and technological know-how for producing its vaccine, the statement said. Fosun Pharma has exclusive rights to supply the vaccine in the Chinese mainland, Hong Kong, Macao, and Taiwan.  On Monday, BioNTech also announced plans to set up its regional headquarters in Singapore and establish an integrated mRNA manufacturing unit in the country. The Singapore facility will “provide regional and global supply capacity” as well as “rapid response production capability,” the company said. https://www.sixthtone.com/news/1007409/chinese-firm-signs-deal-to-produce-pfizer-biontech-vaccine ……………….. Fosun gets ready to make generic Pfizer and Merck Covid-19 pills Pfizer licence to ‘hone Fosun Pharma’s image as a leading player’, after endorsement by UN-backed Medicines Patent Pool, analyst says Parent firm Fosun International reports 26 per cent year-on-year increase in net profit to US$1.6 billion for 2021 Fosun Group Daniel Ren in Shanghai Published: 24 Mar, 2022  A laboratory manufacturing Pfizer’s Paxlovid in Freiburg, Germany. Fosun Pharma is also eligible to produce and supply the raw ingredients for the drug, which is called nirmatrelvir. Photo: AFP Fosun International, one of China’s largest private conglomerates, has stepped up preparations to produce cheaper generic versions of Covid-19 medications developed by American pharmaceutical giants Pfizer and Merck. Its subsidiary Shanghai Fosun Pharmaceutical Group is looking into which of its existing plants can be used to manufacture generic versions of Pfizer’s nirmatrelvir, which is sold under the Paxlovid brand name, and Merck’s molnupiravir, Fosun International co-CEO Chen Qiyu said during an earnings briefing on Thursday. “We are trying to figure out which production base [under Fosun Pharma] will be the ideal place to make the medications,” he said. “Among them, we are considering the factories at our units, such as Guilin Pharma and YaoPharma.” https://www.scmp.com/business/china-business/article/3171731/chinas-fosun-posts-26-cent-jump-net-profit-gets-ready-make ………… Paxlovid is first foreign Covid-19 treatment approved by China
Regulator requires unspecified conditional requirements
https://www.bloomberg.com/news/articles/2022-02-12/china-grants-approval-for-pfizer-s-antiviral-covid-pill?leadSource=uverify%20wall ………………. While we can facilitate partnership with our parent company for the Chinese market, our clear focus is on US rights for innovative biopharmaceuticals. https://fosunpharmausa.com/ Fosun Pharma USA Inc. Pharmaceutical Manufacturing Princeton, NJ A fast-growing pharmaceutical company bringing products to market to improve patient access to medicine and innovation. To Produce Low-cost, Generic Version of Pfizer’s Oral COVID-19 Treatment nirmatrelvir In Combination With ritonavir For Supply in 95 Low- and Middle-income Countries SHANGHAI CHINA, March 18, 2022—Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a subsidiary company of Fosun Pharma, has signed a sublicense agreement with the Medicines Patent Pool (MPP), to manufacture the generic version of Pfizer’s oral COVID-19 treatment nirmatrelvir, which co-packaged with a low dose of ritonavir, can be supplied in 95 low- and middle-income countries (LMICs) comprising approximately 53% of the world’s population. …for the related product under this sublicense are subject to approval by a strict regulatory authority (SRA) or pre-qualified by the World Health Organization (WHO).

Pharma. “As a company with strong social responsibility, Fosun Pharma always takes innovation as a core driving force in our development. In December 2021, the co-packaged product of nirmatrelvir and ritonavir (under the brand PAXLOVIDTM) from Pfizer was authorized emergency use authorization by the US Food and Drug Administration. It was also authorized conditional approval by the European Medicines Agency in January 2022, fast-track approval by the Japanese Ministry of Health, Labour and Welfare in February 2022, and emergency conditional approval by the National Medical Products Administration of China in February 2022. The drug has now approved for emergency use or conditional authorization in more than 50 countries. Through equity participation in Sinopharm Co., Ltd., Fosun Pharma’s business extends to pharmaceutical distribution and retail.
Fosun Pharma takes pharmaceutical manufacturing as its core business and sticks to innovative research and development. Through in-house R&D, co-development, in-licensing and incubation, Fosun Pharma has established platforms for small molecule innovative drugs, antibody drugs and cell therapy, focusing on major therapeutic areas, including oncology, immunology, the “4 hypers” (hypertension, hyperlipidemia, hyperglycemia and hyperuricemia) and their complications, as well as central nervous system. In the meantime, Fosun Pharma keeps close track of cutting-edge technologies, such as targeted protein degradation, RNA, oncolytic virus and gene therapy to enhance its innovation ability.
https://fosunpharmausa.com/fosun-pharma-signs-agreement-with-the-medicines-patent-pool-mpp-2/ …………………….